Cysteine dioxygenase (CDO, EC 1.13.11.20) catalyzes the oxidation of cysteine to cysteine sulfinic acid, which is the first major step in cysteine catabolism in mammalian tissues. Rat liver CDO was cloned and expressed in Escherichia coli as a 26.8-kDa N-terminal fusion protein bearing a polyhistidine tag. Purification by immobilized metal affinity chromatography yielded homogeneous protein, which was catalytically active even in the absence of the secondary protein-A, which has been reported to be essential for activity in partially purified native preparations. As compared with those existing purification protocols for native CDO, the milder conditions used in the isolation of the recombinant CDO allowed a more controlled study of the properties and activity of CDO, clarifying conflicting findings in the literature. Apo-protein was inactive in catalysis and was only activated by iron. Metal analysis of purified recombinant protein indicated that only 10% of the protein contained iron and that the iron was loosely bound to the protein. Kinetic studies showed that the recombinant enzyme displayed a K m value of 2.5 ؎ 0.4 mM at pH 7.5 and 37°C. The enzyme was shown to be specific for L-cysteine oxidation, whereas homocysteine inhibited CDO activity.
Cysteine dioxygenase (CDO) 1 is a metalloenzyme present in mammalian cells (1) and in the yeast Histoplasma capsulatum (2) . It is a non-heme iron-containing enzyme that catalyzes the oxidation of the thiol group of cysteine to yield cysteine sulfinic acid (cysteine sulfinate), the first step in cysteine catabolism and a key intermediate process in taurine synthesis (Scheme 1). Alternatively, cysteine sulfinate can feed to the pyruvate and sulfate pool (3) .
Cysteine dioxygenase has a profound impact on health by reducing the cysteine pool and increasing the levels of important metabolites such as taurine and sulfate. Cysteine is both toxic at high levels and readily oxidizes to form poorly soluble cystine (4) . It has been noted that cysteine elicits excitotoxic behavior by acting on the N-methyl-D-aspartate subtype of glutamate receptor (5) . Other researchers postulate that this amino acid contributes to the formation of reactive oxygen species, oxidizing essential molecules such as the catecholaminergic neurotransmitter dopamine (6) . High levels of this amino acid have been connected to neurological disorders such as motor neuron disease (7), Alzheimer disease, and Parkinson disease (8) . Localized accumulation of cyst(e)ine and decreased activity of CDO has been observed in patients suffering from the rare neurological disorder Hallervorden-Spatz disease (9) . In addition, poor sulfoxidation and the reduced formation of inorganic sulfate are associated with rheumatoid arthritis (10) .
Cysteine dioxygenase supplies the intermediate cysteine sulfinate for taurine formation, which has diverse roles in mammalian organisms such as in bile salt synthesis (11) , in maintaining cardiac function (12) , and in protecting neural cells from excitotoxicity and damage induced by ischemia (13) . It has been postulated that taurine functions as a neurotransmitter because it is the second most abundant amino acid in the central nervous system (14) . Taurine plays a key role in stabilizing mammalian skeletal muscle membrane, and based on studies with aged rats it is hypothesized that changes in muscle function during aging could be associated with a reduction of taurine content (15) .
In the 1960s, it was demonstrated that crude rat liver extracts contain an enzyme that produced L-cysteine sulfinic acid from L-cysteine (16 -20) . Through labeling studies with 18 O 2  and H 2 18 O, Lombardini et al. (21) showed that the enzyme is a dioxygenase.
Early studies on this protein were hampered by the instability of the enzyme to conventional isolation procedures. Cysteine dioxygenase was purified to homogeneity by Yamaguchi et al. (22) , but the process yielded an inactive form of the enzyme. The same research group discovered that the metalloenzyme could be reactivated by preincubation with L-cysteine under anaerobic conditions (23) . The activated enzyme was reported to be rapidly and irreversibly inactivated during aerobic assays, but the inactivation could be prevented by the presence of a second cytosolic protein, protein A. According to Yamaguchi and co-workers (23), protein A does not participate in the catalytic process because neither K m nor the initial reaction velocity is altered by its presence.
The rat liver CDO purified by Yamaguchi and Hosokawa (24) was characterized as a single subunit protein composed of 200 amino acid residues with a molecular mass of 22.5 kDa and a pI value of 5.5. Atomic absorption analysis indicated 0.8 moles of iron per mole of enzyme. Despite numerous reports that confirm the 22.5-kDa mass of CDO, a stable protein of 68 kDa was recently reported by Waring and co-workers (25, 26) . This protein did not dissociate even in the presence of SDS and reducing agents at boiling temperatures.
In the present study, we report the cloning, overexpression in Escherichia coli, purification, and characterization of recombinant rat liver cysteine dioxygenase. The findings obtained using homogeneous recombinant protein purified under mild conditions provide insights into the properties and activity of this important enzyme in the cysteine metabolic pathway and clarify conflicting results in the literature.
MATERIALS AND METHODS
Chemicals-Sodium phosphate, sodium chloride, ferrous sulfate, and cobalt sulfate were purchased from Fisher Scientific, and imidazole was from Acros Organics. Tryptone, yeast extract, ammonium acetate, chloramphenicol, ampicillin, MES, phenylmethylsulfonyl fluoride, isopropyl ␤-D-thiogalactopyranoside, and EDTA were obtained from Sigma. 1,10-Phenanthroline monohydrate was acquired from Avocado Research Chemicals. Cysteine, homocysteine, cysteine sulfinic acid, and heptafluorobutyric acid (HFBA) were obtained from Aldrich Chemical Co. All chemicals were used as received. Biotinylated thrombin was purchased from Novagen, Inc.
Amplification of Cysteine Dioxygenase cDNA Sequence-Amplification of CDO cDNA was done with reverse transcription-PCR. Primers were designed based on the CDO cDNA sequence published by Hosokawa et al. (27) . First-strand rat liver CDO cDNA was made from 1 g of total rat liver RNA, using the primer 5Ј-GCTTGTGGTTTCT-TCATTTTTAC-3Ј corresponding to nucleotides 1119 to 1141 of the CDO cDNA. Superscript II RNase H Ϫ reverse transcriptase was utilized in the synthesis of the CDO clone. A standard PCR reaction with forward and reverse primers corresponding to nucleotides 155-171 and 863-880, respectively, of CDO cDNA, was carried out with Taq polymerase to amplify the newly synthesized CDO clone. In addition to the required CDO sequence, the forward primer contained an XhoI restriction site and the reverse primer a BamHI restriction site to facilitate insertion of the amplified fragment in the sense orientation into the pET-14b vector. The identity of recombinant clones as CDO cDNA was confirmed by the dideoxynucleotide chain termination method (28) . Finally, the amplified fragment was cloned into a pET-14b vector.
Overexpression and Purification of Rat Liver CDO in E. coli-The CDO open reading frame was subcloned into the pET-14b vector, and the pET-14b/CDO-ORF plasmid was then transferred into the E. coli strain BL21(D3)pLysS. 1.5 liter of bacterial cells were grown in LB medium at 22°C for 8 h to an A 580 of 0.5, after which expression of the recombinant CDO protein was induced by addition of 200 M isopropyl ␤-D-thiogalactopyranoside and supplemented with 200 M ferrous ammonium sulfate. Cells were harvested by centrifugation and resuspended in 50 mM sodium phosphate buffer, pH 8.0, containing 300 mM sodium chloride and 10 mM imidazole. The suspension was kept frozen at Ϫ80°C for subsequent analysis, after which the cells were lysed by thawing the solution in the presence of phenylmethylsulfonyl fluoride and DNase I. The cell extract was loaded onto a column containing 25 ml of nickel-nitrilotriacetic acid and washed with 2 liter of 50 mM sodium phosphate buffer, pH 8.0, with 300 mM sodium chloride and 30 mM imidazole. Elution of the fusion protein was accomplished with 300 mM imidazole in the same phosphate buffer solution. Removal of imidazole and buffer exchange were carried out by ultrafiltration using a 10-kDa molecular mass cut off membrane. The samples were analyzed by SDS-PAGE using the Laemmli method (29).
Measurement of Cysteine Sulfinic Acid by High Performance Liquid
Chromatography (HPLC)-The purified protein was tested for activity by incubating the protein with L-cysteine, and the product of the reaction was determined by ion pair reversed-phase HPLC using a Particil 10 ODS-3 C 18 column. The samples were ultrafiltered using a 10-kDa membrane prior to injection. Isocratic analysis of a 50-l injected sample solution was achieved using a mobile phase system composed of 99.4:0.6 (v/v) water:methanol with 0.3% HFBA at a flow rate of 0.5 ml/min and detection at 215 nm. The peak eluting at 6.5 min was confirmed to be the product cysteine sulfinic acid (CSA) by retention time comparison with standards.
His Tag Removal from the Recombinant CDO and the Activity of CDO without the Fusion Tag-To examine the possible competition between the His tag and enzyme active site for iron, the His tag was removed using an N-terminal thrombin cleavage site. Recombinant CDO (320 l of 1.38 mg/ml) was dissolved in 0.2 M ammonium acetate and 0.1 M sodium chloride at pH 7.5 and mixed with 120 l of 10ϫ thrombin cleavage buffer, 80 l of thrombin solution (ϳ0.04 units of thrombin per l), and 160 l of deionized water and left for 5 days at room temperature. The thrombin cleavage reaction was monitored at different time intervals by electrospray ionization mass spectrometry, which showed that 5 days were required for complete cleavage. The activity was monitored during this period, and no loss of activity was observed. After completion of the cleavage reaction, the thrombin cleavage buffer was replaced by 50 mM ammonium acetate solution by using ultrafiltration with 10-kDa molecular mass cut off ultrafiltration tubes. This sample was sent for electrospray ionization mass spectrometry analysis, which confirmed the expected molecular mass (see below). The activity of the thrombin cleavage product was determined from a portion of this sample (20 l) by incubating it with 980 l of 33 mM cysteine in 0.2 M ammonium acetate with 0.1 M sodium chloride at pH 7.5 at 37°C for 3 h. The activity obtained was compared with that of the recombinant enzyme prior to thrombin cleavage under identical conditions. Activities of CDO with and without the His tag were also determined in the presence of excess ferrous ions. To 30 l of each CDO sample was added 770 l of 100 mM cysteine and a volume of a 19.1 mM solution of ferrous chloride sufficient to provide a 1000ϫ molar excess of Fe 2ϩ . The final volume was adjusted to 1 ml, and the sample was incubated for 2 h at 37°C.
RESULTS
The use of immobilized metal affinity chromatography has been shown to be a relatively simple and fast way to obtain homogeneous solution of recombinant cysteine dioxygenase, avoiding the tedious and complex purification protocol reported by Yamaguchi and Hosokawa (24) . With its 235 amino acids, the recombinant protein has a molecular mass of 26.8 kDa. SDS-PAGE analysis was used to monitor the purification of recombinant CDO. At an earlier stage of the project, our investigations were hindered by the presence of inclusion bodies when the culture was grown at 37°C; this problem was overcome by lowering the temperature to 22°C together with iron supplementation.
Anion exchange chromatography has been used by other investigators in the determination of cysteine sulfinic acid, which required that sample pretreatment remove cysteine and other cations from solution (30) . We used reversed-phase liquid chromatography because of its precision and robustness at different types and amount of salt in the sample buffer. By using the ion pair agent HFBA, the very polar molecule cysteine sulfinic acid could be retained and separated from other compounds. The use of trifluoroacetic acid, a shorter analytical column, or a higher organic percentage in the mobile phase could not prevent CSA from eluting at the void volume. The negative peaks (system peaks) observed in the chromatogram are typically found in HPLC analysis using UV detection and mobile phases containing components that give a measurable detector response (31) .
The purified recombinant CDO showed the continuous formation of the product CSA for over 30 h as illustrated in Fig. 1  (inset) . The reaction solution contained only the enzyme and the substrate cysteine with no additional cofactor or protein. We also investigated the effect of anaerobic preincubation of the recombinant CDO in the presence of cysteine for 30 min (Fig. 1) . We observed an initial increase in the amount of CSA produced with this anaerobic preincubation, but the activity of the pre-incubated sample became indistinguishable from the sample without pretreatment after 120 min.
We have investigated the Michaelis-Menten constant for the recombinant protein (Fig. 2) . Bagley et al. (30) reported a maximal activity at a substrate concentration of 5 mmol/L cysteine, whereas the Yamaguchi group (22) determined a K m value of 0.45 mmol/liter. Our studies indicated a K m of 2.5 Ϯ 0.4 mM, corresponding to half the maximal value stated by Bagley.
Several optimal pH values for CDO activity have been stated in the literature, ranging from 6.1-9.0. In our studies, we observed that a pH of 7.5 provides the maximum activity (Fig.  2, inset) , which is reasonable given the pH in the cytosol.
The purified recombinant CDO was subjected to metal analysis by graphite furnace atomic absorption spectroscopy to quantitate the amount of iron present. The results revealed that only 10% of the as-isolated protein contained iron, implying a loosely bound iron in the metallocenter, which is observed in several other mononuclear non-heme iron oxygenases (32) (33) (34) . The activity of the as-purified CDO increased when incubated with excess Fe 2ϩ (Fig. 3A) . To establish that the reaction is in fact catalyzed by iron, the activity of the protein was also evaluated in the presence of the metal chelators, EDTA and o-phenanthroline (Fig. 3B) . As expected, the activity diminished with increasing concentrations of the chelators. EDTA was also used to prepare apo-protein, and after removing the chelating agent, the activity of the metal-free CDO was compared with reconstituted enzyme (Fig. 4A) . Essentially no activity was observed for the apo-enzyme.
Among several metals commonly found in metalloenzymes, including manganese, cobalt, copper, and nickel, iron was the only metal that could reactivate the enzyme after being treated with chelating agents. However, cobalt ions in the reaction solution slowed down CDO activity as demonstrated in Fig. 4B .
To assess the effect of the His tag present in the recombinant protein on iron binding and the activity of recombinant CDO, the fusion peptide was removed by cleavage with thrombin, which recognizes the sequence Leu-Val-Pro-Arg-Gly-Ser, cleaving between the Arg-17 and Gly-18 residues in recombinant   FIG. 1 . Activity comparison of recombinant cysteine dioxygenase with (E) and without (Ⅺ) anaerobic preincubation. Aerobic samples were prepared by dissolving 0.13 g of L-cysteine in 9 ml of solution containing 0.08 mg/ml cysteine dioxygenase in MES buffer, pH 6.1, at 37°C. Small aliquots of the solution were taken at different time intervals, and the reaction was terminated by he addition of 5 l of HFBA. Identical samples were prepared following anaerobic preincubation with cysteine using a N 2 -purged enzyme solution under anaerobic conditions in a Coy chamber 30 min prior to exposure to air. The reaction without preincubation was allowed to continue for an extended period of time (inset); 0.13 g of L-cysteine was dissolved in 9 ml of solution containing 0.08 mg/ml cysteine dioxygenase in MES buffer, pH 6.1, at 37°C. Small aliquots of the solution were taken at different time intervals, and the reaction wad terminated by the addition of 5 l of HFBA. The samples were then analyzed by HPLC.
FIG. 2. Michaelis-Menten kinetics of recombinant cysteine dioxygenase.
The assay was performed at protein concentrations of 13.9 g/ml (E) and 27.8 g/ml (Ⅺ). The assay was initiated by the addition of 50, 80, 120, 180, 350, 500, and 700 l of freshly prepared L-cysteine stock solution (0.05 g in 200 mM ammonium acetate at pH 7.5) to seven different flasks containing 100 or 200 l of 0.125 mg/ml CDO solution together with ammonium acetate buffer to make a final volume of 900 l. The solutions were kept at 37°C for 3 h, after which the reactions were terminated by the addition of HFBA and analyzed by HPLC. Also shown is the initial rate of cysteine oxidation by cysteine dioxygenase at various pH values (inset); aliquots (3 ml) of L-cysteine stock solutions (4.1 mM) prepared in either 200 mM phosphate buffer (for pH values 5.5-9.4) or carbonate buffer (for pH value 10.1) were added to 300 l of 0.35 mg/ml CDO solution. The solution was kept at 37°C for 2.5 h, after which the reaction was terminated by the addition of HFBA, and the products were analyzed by HPLC. The pH value of 7.5 was determined to be the optimum.
CDO. Electrospray ionization mass spectrometry confirmed the expected mass of 24,951 Da for the thrombin cleavage product with an observed mass of 24,951.90 Ϯ 4.49 Da. Comparisons of the activity of recombinant CDO with and without the His tag showed no significant difference. The intact fusion protein had an activity of 17.3 M CSA/(mg CDO ϫ min), whereas that treated with thrombin gave a value of 17.4 M CSA/(mg CDO ϫ min). In the presence of excess Fe 2ϩ at a molar ratio of 1000, CDO with the His tag showed an increase in activity of 20%, whereas the activity of the thrombin cleavage product increased 23%.
Recombinant cysteine dioxygenase was observed to be highly specific for L-cysteine. Methionine and homocysteine were not shown to be potential substrates, and the latter displayed inhibitory effects. Fig. 5 illustrates an inverse relation between CSA production and homocysteine concentration. CDO activity declined by 50% at homocysteine levels of 6.5 mM, at which point the inhibitor concentration is 2.6 times higher than that of the substrate.
DISCUSSION
Recombinant rat liver CDO was expressed and purified to homogeneity and shown to be catalytically active in converting L-cysteine to CSA. It has been reported that cysteine dioxygenase is rapidly and irreversibly inactivated during assay, which is prevented by protein A (35) . The recombinant CDO purified in our research group was catalytically active and did not require the presence of a second protein to be functionally active, as it was observed continuous production of CSA for over 30 h (Fig. 1, inset) . Clearly, the enzyme was not deactivated by oxygen, and protein A was not required for activity.
The need for anaerobic preincubation of the enzyme with the FIG . 3 . A, recombinant cysteine dioxygenase activity in the presence of excess ferrous ions. As-isolated recombinant CDO with (E) and without (Ⅺ) additional iron ions in the reaction solution. A solution containing CDO (1.1 mg/ml, 0.2 ml) and cysteine (8.3 mM, 4.35 ml) was incubated at 37°C with either ferrous sulfate (1.8 mM, 0.1 ml) or with buffer (0.2 M ammonium acetate, 0.1 M sodium chloride, pH 7.5, 0.1 ml). Aliquots were taken for HPLC analysis after quenching the reaction with HFBA. B, also shown is the inhibition of cysteine dioxygenase activity by EDTA (•) and o-phenanthroline (E); aliquots (0.7 ml) of a solution containing 0.39 mg/ml CDO were incubated in the presence of either 0, 0.036, 0.91, or 11 mM EDTA for 9 h at room temperature, after which the assay was started by addition of cysteine (24.8 mM, 0.2 ml) to give a final substrate concentration of 5.5 mM. The reaction was terminated after 3 h by the addition of HFBA. An EDTA concentration of 0.60 mM is required to decrease the synthesis of CSA by 50%. Inhibition by o-phenanthroline was examined by incubating aliquots (0.5 ml) of a solution containing 0.33 mg/ml CDO in the presence of either 0, 0.08, 0.40, 1.2, or 2.4 mM o-phenanthroline for 7 h, after which cysteine (24.8 mM, 0.2 ml) was added to the mixture. The reaction was allowed to continue for 3.5 h and was stopped by addition of HFBA, and the products were analyzed by HPLC. An o-phenanthroline concentration of 0.33 mM was required to inhibit CDO by half.
FIG. 4.
A, activity comparison between apo-enzyme and enzyme reconstituted with ferrous ions. A solution of CDO (300 l of 3.4 mg/ml) was treated with EDTA for 9 h at room temperature, and then the EDTA was removed by ultrafiltration. The apo-CDO sample was then combined with 4.2 ml of 23 mM cysteine and with either 600 l of 1.8 mM ferrous sulfate (•) or 600 l of 0.2 M ammonium acetate with 0.1 M NaCl at pH 7.5 (E). The solutions were incubated at 37°C, and 1-ml aliquots were taken at different intervals. HFBA was added to the fractions to quench the reaction prior to HPLC analysis. B, effect of enzyme incubation with cobalt ions. An aliquot of a solution containing CDO (5.15 ml, 0.048 mg/ml) and 9.9 mM cysteine in 0.2 M ammonium acetate with 0.1 M NaCl at pH 7.5 was incubated at 37°C in the presence of 0.17 mM cobalt sulfate (E) or absence of cobalt ions (•). The assay was performed in duplicate.
FIG. 5. CDO inhibition by homocysteine.
Four samples were prepared by combining a solution of the enzyme (1.1 mg/ml, 50 l) with a solution of cysteine (16.5 mM, 150 l) with aliquots of a stock solution of homocysteine (29.6 mM; 0, 30, 400, 800 l). Buffer was used to bring the final volume to 1 ml. These samples were left in a water bath at 37°C for 3 h, after which HFBA was added to terminate the reaction, and the products were analyzed by HPLC. With a homocysteine concentration of 6.5 mM, the activity of CDO declined by 50%.
substrate to achieve maximal reactivity was also indicated in the literature (1). We observed an initial increase in the amount of CSA produced with 30-min preincubation under anaerobic conditions (Fig. 1) . The initial rate (as demonstrated by the slopes in the figure) with the preincubation was about 40% higher than without it. This difference was no longer apparent after 120 min. Because the enzyme was clearly active without preincubation, and because assays without the anaerobic pretreatment provided a linear increase of CSA over the time analyzed, anaerobic preincubation was not used for further kinetic studies.
The recombinant enzyme displayed a K m value of 2.5 Ϯ 0.4 mM at 37°C and at the optimum pH value of 7.5. Metal analysis indicated 10% iron incorporation into the as-isolated protein, which was inactivated by the presence of EDTA and o-phenanthroline. The activity of the apo-enzyme could be restored by reconstitution with Fe 2ϩ . Iron was kept in the Fe 2ϩ form during the assay by using large amounts of cysteine, which reduces Fe(III) to Fe(II). The possibility that the His tag could affect the binding of iron in the active site or the enzyme kinetics was examined by cleaving the N-terminal fusion peptide with thrombin, which recognizes the amino acids Leu-Val-Pro-ArgGly-Ser and cleaves recombinant CDO between Arg-17 and Gly-18, removing the His tag. To ensure complete digestion, CDO was incubated with thrombin for an extended period. Under these conditions, a small amount of cleavage at another site was also detected by electrospray ionization mass spectrometry. This cleavage occurs between Ala-34 and Gly-35 and is also within the fusion peptide. The thrombin cleavage product had an activity that was indistinguishable from the recombinant CDO with an intact His tag. As the presence of additional ferrous ions was shown to increase enzyme activity, intact recombinant CDO and the thrombin cleavage product were assayed in the presence of excess Fe 2ϩ . Similar increases in activity were observed for both CDO samples (20 and 23% for CDO with and without the His tag, respectively).
Interestingly, cobalt in the reaction solution was shown to inhibit CDO activity (Fig. 4B) . Presumably, cobalt displaces iron from the active site or otherwise hinders iron binding, thereby reducing the catalytic activity of the enzyme.
The recombinant enzyme appeared to be highly specific for cysteine oxidation. Methionine and homocysteine were not shown to be substrates for CDO, however the latter inhibited CDO activity suggesting that homocysteine may have a direct impact on cysteine metabolism. High levels of homocysteine together with elevated amounts of cysteine have been observed in diseases such as in Alzheimer disease (36) , raising the possibility that the increase in cysteine levels is a result of CDO inhibition by homocysteine.
